GC012F

Phase 1Cell therapy

GGracell Biotechnologies (Shanghai) Co., Ltd.

GC012F is one of 186 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

185

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

AL AmyloidosisActive, not recruiting

Autoimmune DiseaseActive, not recruiting

Multiple MyelomaActive, not recruiting

Myasthenia GravisActive, not recruiting

Idiopathic Inflammatory MyopathyActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

AL AmyloidosisPhase 1

Active, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Myasthenia GravisPhase 1

Active, not recruiting

Idiopathic Inflammatory MyopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

GC012F

GGracell Biotechnologies (Shanghai) Co., Ltd.

Phase 1

4 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT06530849

Q3 2027

Phase 1Recruiting

Myasthenia Gravis

NCT07058298

Phase 1Not yet recruiting

Myasthenia Gravis

NCT06759948

Q4 2028

PreclinicalRecruiting

Relapsed/refractory Multiple Myeloma

NCT05850234

Phase 1Recruiting

AL Amyloidosis

NCT07250269

Q1 2029

Phase 1Not yet recruiting

Autoimmune Disease

NCT07072884

Clinical

Trials by Indication[1]

Multiple Myeloma4 trials

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Unknown status·SShanghai Changzheng Hospital·Phase 1·NCT04236011·15 enrolled

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Unknown status·SShanghai Changzheng Hospital·Phase 1·NCT04617704·15 enrolled

Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

Unknown status·SShanghai Changzheng Hospital·Phase 1·NCT05412329·9 enrolled

Show 1 more trial

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·GGracell Biotechnologies (Shanghai) Co., Ltd.·Phase 1/2·NCT06235229·110 enrolled

Systemic Lupus Erythematosus3 trials

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Recruiting·GGracell Biotechnologies (Shanghai) Co., Ltd.·Phase 1·NCT06530849·18 enrolled

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Unknown status·RRenJi Hospital·Phase 1·NCT05858684·18 enrolled

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

Unknown status·ZZhejiang University·Phase 1·NCT05846347·15 enrolled

Myasthenia Gravis2 trials

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

Recruiting·DDaishi Tian·Phase 1·NCT07058298·6 enrolled

An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis

Not yet recruiting·CChongbo Zhao·Phase 1·NCT06759948·18 enrolled

Refractory1 trial

An Exploratory Clinical Study of GC012F Injection for Refractory gMG

Withdrawn·ZZhejiang University·Phase 1·NCT06419166

CAR-T1 trial

Study of FasT CAR-T GC012F Injection NDMM Patients

Unknown status·SShanghai Changzheng Hospital·Phase 1·NCT05840107·18 enrolled

5 more indications

Idiopathic Inflammatory Myopathy1 trial

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

Recruiting·DDaishi Tian·Phase 1·NCT07086404·12 enrolled

Autoimmune Disease1 trial

GC012F in Patients With Autoimmune Diseases

Not yet recruiting·QQiong Fu·Phase 1·NCT07072884·15 enrolled

AL amyloidosis1 trial

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Recruiting·GGracell Biotechnologies (Shanghai) Co., Ltd.·Phase 1·NCT07250269·9 enrolled

High Risk1 trial

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Unknown status·SShanghai Changzheng Hospital·Phase 1/2·NCT04935580·20 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT05850234·182 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for GC012F. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GC012F compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GC012F. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gracell Biotechnologies (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: GGracell Biotechnologies (Shanghai) Co., Ltd.

GC012F

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2028

Q1 2029

Trials by Indication[1]

Multiple Myeloma4 trials

Systemic Lupus Erythematosus3 trials

Myasthenia Gravis2 trials

Refractory1 trial

CAR-T1 trial

Idiopathic Inflammatory Myopathy1 trial

Autoimmune Disease1 trial

AL amyloidosis1 trial

High Risk1 trial

Relapsed/Refractory Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News